US Stock Market Move | Biopharmaceutical company Maplight Therapeutics (MPLT.US) listed on the US stock market, with its stock price rising more than 15.8%.
As of the publication, the stock has risen by more than 15.8%, trading at $19.7.
On Monday, the biopharmaceutical company Maplight Therapeutics (MPLT.US) made its debut on the US stock market, and as of the time of this report, the stock rose over 15.8% to $19.7. The IPO price was $17. MapLight was founded by internationally renowned leaders in psychiatry and neuroscience research, aiming to address the lack of drug therapy targeting specific neural circuits in patients.
MapLight claims that its platform can identify neural circuits causally related to diseases and regulate treatment for these circuits. The company has developed a range of candidate products for treating some of the most challenging central nervous system diseases, such as schizophrenia, Alzheimer's disease, and autism spectrum disorders.
Related Articles
US Stock Market Move | Strive (ASST.US) surged by 35% in the past 3 trading days, with a total increase of 92%.
The U.S. Department of Energy is partnering with AMD (AMD.US) to build two AI supercomputers to accelerate scientific breakthroughs in nuclear energy, cancer drugs, and more.
US Stock Market Move | Pause patient dosing and screening for the phase III clinical trial of NEX-Z caused Intellia Therapeutics (NTLA.US) to plummet over 45%.
US Stock Market Move | Strive (ASST.US) surged by 35% in the past 3 trading days, with a total increase of 92%.
The U.S. Department of Energy is partnering with AMD (AMD.US) to build two AI supercomputers to accelerate scientific breakthroughs in nuclear energy, cancer drugs, and more.
US Stock Market Move | Pause patient dosing and screening for the phase III clinical trial of NEX-Z caused Intellia Therapeutics (NTLA.US) to plummet over 45%.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
